Tuesday, January 25, 2022 10:07:39 AM
highwayman4life,
I used to post once in a while on another MB as Edwardmonighan146 (long story for the name) a few years ago and I recall you being the voice of reason on that board, you carried a big load on that board back then if I remember correctly.
When safety/ethics descriptors are used as such general terms by ex it covers about everything. A trial can be interrupted if proper controls are not being executed properly and that would be considered safety. Clinical trial controls are predominantly about patient safety. And ethics could include the possibility of dosing patients with placebo when it is apparent there is benefit from the therapy. I think the main question that remains from the partial clinical hold is why were only placebo patients restricted? And this does not appear to be bad news in my opinion.
I used to post once in a while on another MB as Edwardmonighan146 (long story for the name) a few years ago and I recall you being the voice of reason on that board, you carried a big load on that board back then if I remember correctly.
When safety/ethics descriptors are used as such general terms by ex it covers about everything. A trial can be interrupted if proper controls are not being executed properly and that would be considered safety. Clinical trial controls are predominantly about patient safety. And ethics could include the possibility of dosing patients with placebo when it is apparent there is benefit from the therapy. I think the main question that remains from the partial clinical hold is why were only placebo patients restricted? And this does not appear to be bad news in my opinion.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
